Trump tariff unlikely to be a bitter pill for pharma - Everything you need to know

While US President Donald Trump announced the likely imposition of 25 per cent tariffs on imported pharmaceuticals, Kotak Institutional Equities (KIE) analysed the base and worst case scenarios in the event of the tariff hike.
Read more...